Articles By RheumNow
Doubling Down on IL-17 In Psoriatic Arthritis
By RheumNow
The monoclonal antibody bimekizumab, which neutralizes both interleukin (IL)-17A and 17F, was effective for both musculoskeletal and skin outcomes in psoriatic arthritis (PsA) in a phase IIb study.
Read Article
'These Results Are Astonishing': What We Heard at ACR 2018
By RheumNow
"If radiation was a drug that could improve survival in the metastatic setting like that it would be millions and millions of dollars." -- James B. Yu, of Yale Cancer Center, discussing aggressive use of stereotactic body radiation therapy in oligometastatic cancer.
Read Article
Treat-to-Target Strategy Cuts Mortality in Gout Patients
By RheumNow
More intense treatment of gout with a treat-to-target strategy can reduce patients' risk for death, a Spanish researcher told a press conference Monday at the American College of Rheumatology annual meeting here.
Read Article
IL-6 for Adult Still's: A New Option?
By RheumNow
Some clinical benefits were seen among patients with adult-onset Still's disease treated with tocilizumab (Actemra) in a small clinical trial, but the study's primary endpoint was not met, Japanese researchers reported.
Read Article
NSAIDs OK for Certain High-Risk Groups?
By RheumNow
Some patients typically contraindicated for prescription nonsteroidal anti-inflammatory drug (NSAID) use may be able to take them with no increased risk of harm, according to a large observational study.
Read Article
Complex Pain Syndromes in the Emergency Room
By RheumNow
Emergency physician Chris Hahn, MD, doesn't have any trouble conjuring a simple definition of fibromyalgia. "Just think about the most annoying chief complaints you can imagine. That's the diagnostic criteria."
Read Article
Activity Trackers May be Helpful in Arthritis Patients
By RheumNow
Use of wearable activity trackers was associated with increases in the number of daily steps among individuals with rheumatic and musculoskeletal disorders, a meta-analysis found.
Read ArticleMortality Improves in Lupus ESRD
By RheumNow
The past two decades have seen a significant decline in mortality among patients with lupus nephritis, U.S. registry data indicated.
Read Article
Treat-to-Target in RA: No Increase in AEs
By RheumNow
Implementing a treat-to-target approach for the care of rheumatoid arthritis (RA) did not result in an increase in adverse events or resource use, a post-hoc analysis of a randomized trial showed.
Read Article
Cutting Oral JAK 1/2 Inhibitor Dose an Option in RA
By RheumNow
Many patients with rheumatoid arthritis (RA) who achieved sustained disease control with baricitinib (Olumiant) treatment were able to reduce their daily dose from 4 mg to 2 mg and maintain their response, a double-blind substudy of a long-term extension trial found.
Read Article